Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
2.060
+0.010 (0.49%)
Jan 21, 2025, 4:00 PM EST - Market closed
Neumora Therapeutics Stock Forecast
NMRA's stock price has decreased by -85.54% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for NMRA stock have an average target of 20.67, with a low estimate of 7.00 and a high estimate of 30. The average target predicts an increase of 903.40% from the current stock price of 2.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NMRA stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 3 |
| Buy | 4 | 4 | 3 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $22 → $7 | Strong Buy | Maintains | $22 → $7 | +239.81% | Jan 6, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,356.31% | Jan 3, 2025 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +1,016.50% | Jan 2, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,356.31% | Dec 16, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $29 | Buy | Reiterates | $29 | +1,307.77% | Nov 22, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.64
from -3.63
EPS Next Year
-1.70
from -1.64
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | 82.3M | |||
| Avg | n/a | n/a | 31.8M | |||
| Low | n/a | n/a | 6.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.64 | -1.42 | -1.21 | |||
| Avg | -1.64 | -1.70 | -1.76 | |||
| Low | -1.60 | -1.90 | -2.06 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.